ProSense
Commercial- Indications
- Premature ejaculation
Company intelligence / Profile preview
Virility Medical has developed and commercialized the world’s first FDA-cleared, CE-marked wearable device that uses low-frequency electrical stimulation to contract pelvic-floor muscles, thereby delaying ejaculation. The product has been clinically proven in trials to be effective as a drug-free, discreet solution for premature ejaculation. The company’s main product ("in2" device) is available in the United States and Israel. Clinical data supports its efficacy with immediate effect upon use.
2 more assets in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Virility Medical.